Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02684097 · ClinicalTrials.gov registry record · Phase 2
A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata
A Phase 2 study, sponsored by Emma Guttman.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT02684097 is a Phase 2 study that has completed, run by Emma Guttman. The registered enrollment target is 22 participants.
The verdict
NCT02684097, a Phase 2 study, has completed, sponsored by Emma Guttman.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to assess whether tralokinumab can be a helpful treatment for alopecia areata. This is a randomized, double-blind, placebo-controlled pilot study of a total of 30 subjects with moderate to severe alopecia areata involving 30-100% of the scalp. Expected is 50% of these subjects to have concomitant alopecia areata (AA) and atopic dermatitis (AD). Subjects with AA alone (15 subjects) will be randomized (2:1) to either receive tralokinumab or placebo via subcutaneous injection every 2 weeks for 24 weeks. Subjects with concomitant alopecia areata and atopic dermatitis (15 subjects) will be randomized separately in a 2:1 ratio to receive tralokinumab or placebo via subcutaneous injection every 2 weeks for 24 weeks.
Interventions
- DRUG Placebo
- DRUG Tralokinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2016-01 |
| Est. Completion | 2017-11-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02684097
The ClinicalTrials.gov registry entry for NCT02684097 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emma Guttman, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02684097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02684097 about?
NCT02684097 is a clinical study titled "A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata". The purpose of this study is to assess whether tralokinumab can be a helpful treatment for alopecia areata. This is a randomized, double-blind, placebo-controlled pilot study of a total of 30 subjects with moderate to severe alopecia areata involving 30-100% of the scalp. Expected is 50% of these su...
What is the current status of trial NCT02684097?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2016-01. Estimated completion is 2017-11-28.
What interventions are being tested in trial NCT02684097?
The interventions under investigation include: Placebo (DRUG), Tralokinumab (DRUG).
Who is sponsoring clinical trial NCT02684097?
This trial is sponsored by Emma Guttman, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.